THE OPPORTUNITY:

The worldwide vaccine market is estimated at approximately $16 billion in total sales, with $12 billion of human vaccines and $4 billion of animal vaccines. While these vaccines address many of the most pressing viral diseases, there is significant opportunity for improvement.

Respiratory syncytial virus (RSV). RSV causes severe respiratory distress among newborns and the elderly. There is no effective vaccine for this viral disease because conventionally prepared RSV vaccines tend to be virulent and can actually cause the disease. MedImmune markets an antibody therapy for infants at-risk for RSV infection, and the product has limited effectiveness, yet generates $800 million in annual revenue. IBI believes that an ICV based technology could render an RSV vaccine safe for widespread pediatric and geriatric use, a market estimated in excess of $1 billion annually.

Seasonal / pandemic influenza. Influenza affects hundreds of millions of people every year, and the young and the elderly are especially susceptible. Although $3.7 billion of influenza vaccine is sold every year, these products don’t protect effectively against different strains of influenza, and the influenza virus tends to evolve from the time it is isolated until the time the vaccines can be created, manufactured, distributed and administered. IBI believe that an ICV based influenza vaccine could improve current influenza vaccines by enhancing their cross-strain protection.

In addition to these human vaccines, ICV technology well suited to addressing unmet needs in a number of animal health applications. These include:

The above examples highlight many diseases where current vaccines result in sub-optimal safety, efficacy or ease-of-use. These represent targets of opportunity for IBI and its ICV technology.